What is the oral (PO) treatment for Enterococcus urinary tract infections (UTIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oral Treatment Options for Enterococcus Urinary Tract Infections

For uncomplicated Enterococcus UTIs, the recommended oral treatments are nitrofurantoin 100mg twice daily for 5 days, fosfomycin 3g single dose, or linezolid 600mg twice daily, with the choice depending on susceptibility testing and infection severity. 1, 2

First-Line Oral Treatment Options

For Uncomplicated Enterococcus UTIs:

  • Nitrofurantoin: 100mg PO every 6 hours or 100mg twice daily for 5 days 1, 3
  • Fosfomycin: 3g PO single dose 1, 3, 2
  • Linezolid: 600mg PO every 12 hours 1

For Vancomycin-Resistant Enterococcus (VRE) UTIs:

  • Linezolid: 600mg PO every 12 hours (strong recommendation for enterococcal infections) 1
  • Nitrofurantoin: 100mg PO every 6 hours (for lower UTIs only) 1, 2
  • Fosfomycin: 3g PO single dose (for uncomplicated UTIs) 1, 2
  • High-dose ampicillin: 500mg PO every 8 hours (if susceptible) 1
  • Amoxicillin: 500mg PO every 8 hours (if susceptible) 3, 2

Treatment Algorithm Based on Clinical Scenario

  1. For uncomplicated lower UTI (cystitis):

    • First obtain urine culture and susceptibility testing
    • Empiric therapy: Nitrofurantoin 100mg twice daily for 5 days or fosfomycin 3g single dose 3
    • Adjust based on susceptibility results
  2. For VRE cystitis:

    • If ampicillin-susceptible: Amoxicillin 500mg PO every 8 hours 1, 2
    • If ampicillin-resistant: Nitrofurantoin 100mg PO every 6 hours or fosfomycin 3g single dose 1, 2, 4
  3. For complicated UTI or pyelonephritis:

    • Linezolid 600mg PO every 12 hours 1
    • Consider parenteral therapy initially if severe symptoms 1

Important Clinical Considerations

  • Duration of therapy:

    • Uncomplicated UTIs: 5-7 days
    • Complicated UTIs: 7-14 days 1
  • Susceptibility testing is crucial as enterococci frequently demonstrate resistance to multiple antibiotics 5, 6

  • Biofilm formation is common in enterococcal UTIs (up to 76.6% of isolates), which may contribute to treatment failure and recurrence 6

  • Avoid fluoroquinolones as empiric therapy due to increasing resistance rates, unless susceptibility is confirmed 3, 5

Special Considerations

  • Aminopenicillins (amoxicillin/ampicillin) may be effective for lower UTIs even when in vitro testing shows resistance, due to high urinary concentrations achieved 7

  • Doxycycline may be considered as an alternative for lower UTIs if other options are unavailable 2

  • For ampicillin-resistant enterococci, nitrofurantoin and fosfomycin remain the most reliable oral options 2, 4

  • Linezolid should be reserved for serious infections or when other options are unavailable due to concerns about resistance development 1, 2

Common Pitfalls to Avoid

  • Don't treat asymptomatic bacteriuria with enterococci, especially in catheterized patients 4

  • Don't use nitrofurantoin for upper UTIs (pyelonephritis) as it doesn't achieve adequate tissue concentrations 1, 2

  • Don't use fluoroquinolones empirically due to high resistance rates 3, 5

  • Don't forget to remove indwelling catheters when possible, as this is a major risk factor for enterococcal UTIs 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Uncomplicated Urinary Tract Infections (UTIs) Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of resistant enterococcal urinary tract infections.

Current infectious disease reports, 2010

Research

Aminopenicillins for treatment of ampicillin-resistant enterococcal urinary tract infections.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.